{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:29:25Z","timestamp":1786418965619,"version":"build-2736575974"},"reference-count":43,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osimertinib has reshaped the treatment of EGFR\u2010mutated non\u2010small cell lung cancer (NSCLC), but its high cost raises persistent questions about value for money.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To review economic evaluations of osimertinib in EGFR\u2010mutated NSCLC and identify the drivers of cost\u2010effectiveness across first\u2010line, second\u2010line\/sequential, and adjuvant settings in North America and Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review was registered with PROSPERO (CRD420251139947) and conducted in accordance with PRISMA 2020. We searched PubMed\/MEDLINE, Embase, Web of Science Core Collection, and the Cochrane Library through August 2025 for peer\u2010reviewed economic evaluations comparing osimertinib with chemotherapy or earlier\u2010generation EGFR tyrosine kinase inhibitors from a payer perspective. Reporting quality was appraised with CHEERS 2022. Given heterogeneity in models, pricing, and survival extrapolation, results were synthesized narratively, each incremental cost\u2010effectiveness ratio (ICER) interpreted against its own jurisdiction's willingness\u2010to\u2010pay (WTP) threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine studies published between 2018 and 2024 were included. First\u2010line osimertinib improved outcomes but at ICERs of $151,922\u2013$231,123\/QALY (US) and \u20ac128,343\u2013\u20ac273,895\/QALY (Europe), exceeding local thresholds. Second\u2010line T790M\u2010positive estimates were favorable and context\u2010dependent ($159,126\/QALY US; \u00a341,705\/QALY UK under end\u2010of\u2010life criteria). Adjuvant results were most divergent: cost\u2010effective under cure\u2010fraction assumptions but unfavorable when benefit was modeled as delayed recurrence. Price, overall\u2010survival (OS) extrapolation, sequencing, and local WTP thresholds were dominant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Osimertinib confers meaningful clinical benefit, but its value for money is context\u2010specific and often uncertain at current list prices. These conclusions rest on few heterogeneous models and warrant caution; sustainable use will depend on price reductions, patient prioritization, maturation of OS data, and outcome\u2010based reimbursement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.72129","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:46:33Z","timestamp":1784720793000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacoeconomic Analysis of Osimertinib Compared to Earlier\u2010Generation\n                    <scp>EGFR<\/scp>\n                    Inhibitors in\n                    <scp>EGFR<\/scp>\n                    \u2010Mutated\n                    <scp>NSCLC<\/scp>\n                    : A Systematic Review"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-5118","authenticated-orcid":false,"given":"Nicola","family":"Perrotta","sequence":"first","affiliation":[{"name":"Policlinico Umberto I Hospital Sapienza University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Coluccia","sequence":"additional","affiliation":[{"name":"Policlinico Umberto I Hospital Sapienza University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[{"name":"Policlinico Umberto I Hospital Sapienza University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Amato","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technology of Drugs Sapienza University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Polito","sequence":"additional","affiliation":[{"name":"Policlinico Umberto I Hospital Sapienza University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70461-9"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2692"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35962-x"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2100"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1395"},{"key":"e_1_2_12_13_1","volume-title":"Osimertinib (Tagrisso): CADTH Reimbursement Review: Therapeutic Area: Non\u2013small Cell Lung Cancer [Internet]","author":"Canadian Agency for Drugs and Technologies in Health","year":"2022"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0029"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01117-3"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08239-8"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.833773"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.9774"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1377718"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-023-00396-0"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac021"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.012"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1300183"},{"key":"e_1_2_12_28_1","volume-title":"Osimertinib for Treating EGFR T790M Mutation\u2010Positive Locally Advanced or Metastatic Non\u2010Small\u2010Cell Lung Cancer. Technology Appraisal Guidance TA653","author":"National Institute for Health and Care Excellence (NICE)","year":"2020"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA5"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02186"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100833"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2022.2011721"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.920479"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1819822"},{"issue":"3","key":"e_1_2_12_36_1","first-page":"740","article-title":"Cost\u2010Effectiveness of Osimertinib in Activating Epidermal Growth Factor Receptor Gene (EGFR)\u2010Mutations in First\u2010Line for Advanced Non\u2010Small Cell Lung Cancer","volume":"4","author":"Giuliani J.","year":"2021","journal-title":"Cancer Drug Resistance"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70083"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.08.024"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1815030"},{"key":"e_1_2_12_40_1","volume-title":"Osimertinib for Adjuvant Treatment of EGFR Mutation\u2010Positive Non\u2010Small\u2010Cell Lung Cancer After Complete Tumour Resection. Technology Appraisal Guidance TA1043","author":"National Institute for Health and Care Excellence (NICE)","year":"2025"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-025-00646-3"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069573"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.1.39"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2694"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72129","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72129","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:56:03Z","timestamp":1786416963000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/cam4.72129"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72129","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72129"}}